The event will be hosted by members of PharmaMar's senior management team and will feature presentations from expert speakers. Management and speakers will discuss scientific pipeline including; Phase 3 pivotal study with lurbinectedin (PM1183), current and prospective clinical trials, small-cell lung cancer and hereditary breast cancers, and an overview of Company strategy. Expert guest speakers to include:
- Melinda Telli, MD, Stanford University, Stanford School of Medicine, Stanford, CA
- Martin Forster, MBBS MRCP PhD, UCL Cancer Institute, University College Hospital, London, UK
- Sue Friedman, DVM, Executive Director of Facing Our Risks of Cancer Empowered (FORCE)
The presentation will be webcast simultaneously on the calendar section of the Company's Events Calendar page of the website at http://www.pharmamar.com
A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the Events Calendar page of the company's website at http://www.pharmamar.com.
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.
Paula Fernández Alarcón